Intravenous may leads to lower relapse at 6 months compared with oral cyclophosphamide (low certainty).
Intravenous may leads to lower continuing frequently‐relapsing or steroid‐dependent SSNS at 6 months compared with oral cyclophosphamide (low certainty).
Intravenous showed no clear difference in relapse at end of study compared with oral cyclophosphamide (low certainty).
The review found no eligible studies for this question.
Intravenous showed no clear difference in adverse events: leucopenia compared with oral cyclophosphamide (low certainty).
Intravenous showed no clear difference in adverse events: hair loss compared with oral cyclophosphamide (low certainty).
Intravenous may leads to lower adverse events: all infections compared with oral cyclophosphamide (low certainty).
It is very uncertain whether intravenous changes adverse events: nausea and vomiting compared with oral cyclophosphamide (very low certainty).